Carregant...
Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiviral (DAA) agents approved, and...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3683992/ https://ncbi.nlm.nih.gov/pubmed/22537438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2012.02.013 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|